复方青黛、ATRA与化疗交替治疗缓解后急性早幼粒细胞白血病

目的: 观察复方青黛片、全反式维A酸(all-trans retinoic acid,ATRA)与化疗交替治疗缓解后急性早幼粒细胞白血病(acute promyelocytic leukemia,APL)临床疗效。方法: 对初诊24例APL患者,先用复方青黛片或ATRA治疗达完全缓解,再用化疗与ATRA、复方青黛片序贯交替治疗,持续缓解3年以上者监测PML/RARα基因,再决定是否停药或继续治疗。结果: 24例全部存活,复发率8.3%,未发现严重副作用。结论: 复方青黛片、ATRA与化疗交替治疗APL疗效满意,副作用少。

Clinical effect of compound qingdai tablets,all-trans retinoic acid and chemotherapy for treatment of acute promyelocytic leukemia of complete remission

Objective: To observe the clinical effect of compound qingdai tablets,all-trans retinoic acid(ATRA) and chemotherapy for the treatment of acute promyelocytic leukemia(APL) of complete remission.Methods: Twenty-four cases of newly diagnosed APL were induced to complete remission by using compound qingdai tablets or ATRA first,then treated alternatively with compound qingdai tablets,ATRA and chemotherapy.We monitored the PML/RARα fusion genes of the patients who maintained remission for 3 years and then decided whether to stop the therapy or continue.Results: All the cases survived.The relapse rate was 8.3% and the side effect was mild.Conclusions: The therapy of sequential use of compound qingdai tablets,ATRA and chemotherapy for treatment of APL of complete remission has the advantages of good results and mild side effects.